



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> <b>A61K 47/36</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 91/04058</b> <b>(43) International Publication Date:</b> 4 April 1991 (04.04.91)
<b>(21) International Application Number:</b> PCT/CA90/00306 <b>(22) International Filing Date:</b> 18 September 1990 (18.09.90) <b>(30) Priority data:</b> 612,307 21 September 1989 (21.09.89) CA <b>(71) Applicant (for all designated States except US):</b> NOR- PHARMCO INC. [CA/CA]; 700 Bay Street, 20th Floor, Toronto, Ontario M5G 1Z6 (CA). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FALK, Rudolf, Edgar [CA/CA]; 57 Rose Park Drive, Toronto, Ontario M4T 1R2 (CA). ASCULAI, Samuel, S. [CA/CA]; 53 McCaul Street, Apt. 252, Toronto, Ontario M6M 2B6 (CA).		<b>(74) Agents:</b> HUGHES, Ivor, M. et al.; 7501 Keele Street, Suite 402, Concord, Ontario L4K 1Y2 (CA).  <b>(81) Designated States:</b> AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE*, DE (European patent)*, DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI pa- tent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> TREATMENT OF CONDITIONS AND DISEASE  <b>(57) Abstract</b>  A combination for administration to a mammal which combination employs a therapeutically effective amount of a medi- cinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or hom- ologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TC	Togo
				US	United States of America